Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Melanoma 23Neoplasms 19Neoplasm Metastasis 19Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 13Skin Neoplasms 12Head and Neck Neoplasms 10Recurrence 9Carcinoma, Renal Cell 9Prostatic Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Carcinoma, Squamous Cell 8Carcinoma, Basal Cell 8Breast Neoplasms 8Urinary Bladder Neoplasms 7Carcinoma, Merkel Cell 7Triple Negative Breast Neoplasms 6Colonic Neoplasms 6Carcinoma 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Pancreatic Neoplasms 5Stomach Neoplasms 4Sarcoma 4Multiple Myeloma 4Mouth Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4

Interventions

Temozolomide 131Radiotherapy 87Bevacizumab 43Radiation 31Carmustine 29Magnetic Resonance Spectroscopy 22Irinotecan 22Erlotinib Hydrochloride 22Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14Radiotherapy, Intensity-Modulated 13Radiotherapy, Conformal 13sargramostim 12Sirolimus 9Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8Thalidomide 8Sorafenib 8Radiosurgery 8pembrolizumab 7motexafin gadolinium 7aldesleukin 7Vorinostat 7Procarbazine 7Gene Expression Profiling 7Gefitinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × cemiplimab × Clear all
NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡